Anti-Phospholamban Antibody, clone 4J16 , ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 4J16 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Cardiac phospholamban. It targets an epitope within 23 amino acids from the N-terminal region.
• Immunogen: KLH-conjugated linear peptide corresponding to 23 amino acids from human Cardiac phospholamban.
• Application: Anti-Phospholamban, clone 4J16 ZooMAb, Cat. No. ZRB1212, is a highly specific rabbit recombinant monoclonal antibody that targets Phospholamban and has been tested for use in Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.
• Target description: Cardiac phospholamban (UniProt: P26678; also known as PLB) is encoded by the PLN (also known as PLB) gene (Gene ID: 5350) in human. Phospholamban is a cardiac muscle-specific, 6 kDa, single-pass membrane protein that is shown to associate reversibly into pentamers. It modulates the contractility of the heart muscle in response to physiological stimuli via its effects on ATP2A2. It modulates calcium re-uptake during muscle relaxation and plays an important role in calcium homeostasis in the heart muscle. The degree of ATP2A2 inhibition depends on the oligomeric state of phospholamban. It is reported to tonically inhibit the SERCA pump by increasing its Km for Ca2+. Phosphorylation of phospholamban by protein kinase A at serine 16 is shown to relieve this inhibition, increasing the SR Ca-ATPase activity and lowering the cytoplasmic [Ca2+]. It can also undergo phosphorylation at threonine 17 by CaMK2 and in response to beta-adrenergic stimulation. Mutations in PLN gene have been linked to cardiomyopathies characterized by ventricular dilation and impaired systolic function that result in congestive heart failure and arrhythmia. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 30 μg/mL after reconstitution at 25 μL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.